NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Recro Pharma, Inc. (NASDAQCM:REPH) concerning possible violations of federal securities laws.
On May 24, 2018, Recro revealed that the U.S. Food & Drug Administration (the “FDA”) had declined to approve Recro’s New Drug Application for the non-opioid pain relief treatment IV meloxicam. The FDA stated in its Complete Response Letter that the drug’s analgesic effects did not meet its expectations and raised questions related to certain data included in the NDA. Following this news, Recro stock fell 54.7% to close at $5.63 per share on May 24, 2018.
If you suffered a loss in Recro and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/recro-pharma-inc.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.